Intelligent Medicine (IQMD), AMCI II (AMCI) Adjourn Shareholder Votes
Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) and AMCI Acquisition Corp. II (Nasdaq: AMCI) announced this afternoon that they have adjourned their special meetings with shareholders.
Intelligent Medicine originally scheduled its meeting to be held today, but is now postponing its vote until Wednesday, February 8. Stockholders may elect to redeem their shares by no later than February 6.
The SPAC announced the pricing of its upsized $150 million IPO in November 2021. Although the SPAC has not yet found a target business to combine with, it intends to focus its efforts on life science companies that are using artificial intelligence, machine learning and big data to power drug discovery.
As for AMCI II, its special meeting, which was also scheduled for today, has been postponed until Monday, February 6. This marks the second adjournment for its meeting as it hopes to complete its transaction with sustainable materials-maker LanzaTech.
AMCI inked its $1.8 billion deal with LanzaTech in March 2022. The Chicago-based company is developing carbon-capture plants designed to provide a number of carbon negative outputs ranging from jet fuel to consumer packaging materials.